The three IT musketeers – AI, high tech, quantum computing! NetraMark Holdings, Bayer, Novo Nordisk, and D-Wave

NetraMark Holdings – Revolutionizing results, reducing costs

Pharmaceuticals used to be an industry where the sun always shone, but now things are going downhill. Examples such as Bayer and Pfizer show where share prices can end up when costs get out of hand. US President Donald Trump is also unhappy about the high margins in the pharmaceutical industry. He wants to halve prices while making the US an attractive location. This is a major challenge that can only be solved with technology. Some industry representatives have recognized the signs of the times and are stepping on the gas. What NVIDIA's CEO recently shared in Paris is already daily practice for the Canadian AI technology company NetraMark Holdings Inc. (AIAI). Big data analytics and artificial intelligence (AI) applications have been used successfully in clinical trials for some time now, speeding up processes, significantly reducing costs, and dramatically increasing validity. AI can analyze large amounts of data from electronic health records, genome data, and patient registries to identify suitable participants for clinical trials more quickly and accurately. This significantly shortens recruitment times and improves accuracy. It is too early to say whether quantum computers will also be used in the near future.

The pharmaceutical industry is the major client for NetraMark's projects, as it is increasingly using artificial intelligence to make clinical trials more accurate and cost-effective. The results so far point to a quantum leap, as the NetraAI 2.0 platform addresses one of the most pressing challenges in clinical research: the interface between efficacy and feasibility. CEO George Achilleos knows that a high percentage of all clinical trials fail, especially in Phases 2 and 3, which is why the Company is working intensively to revolutionize the results of these trials through improved design and evaluation methods.

Investors discovered the stock at low cent prices in 2024, and since then, a revaluation has taken place. Now, however, investors also know how dynamically the business can develop. With gross margins of over 90%, the current valuation of CAD 112 million certainly reflects the intrinsic value of the business model. Given the high level of momentum, investors should consider positioning themselves early, as further development milestones can be reported at any time! Then the next rocket will take off.

CEO George Achilleos presented NetraMark Holdings at the 15th International Investment Forum on May 21, 2025. Click here for the video.

Novo Nordisk and Bayer – Lots of potential to catch up

Novo Nordisk and Bayer are two major players in the European pharmaceutical sector. Both experienced a huge sell-off of their shares, which in Bayer's case was due to the dire situation caused by glyphosate lawsuits in the US. The acquired Monsanto businesses are already facing bankruptcy if the highest courts rule against the Company. In the case of Novo Nordisk, the slump was due to lower expectations for the obesity drug business due to emerging competition. Both companies are currently undergoing a tough restructuring process and are incorporating AI into their operating processes in order to save further costs. Bayer launched a collaboration with Exscientia in 2020. The aim is to support the AI-assisted discovery of new drug candidates in the fields of cardiology and oncology. Generative AI is used to predict optimal reaction conditions in chemical syntheses. Bayer uses AI specifically for target identification, molecule design, and optimized laboratory processes.

Novo Nordisk uses AI for drug design, patient selection, and research and development. To this end, it has been working since 2024 on an AI platform from Microsoft Research to build a cloud-based research infrastructure, including data integration from 1,600 past studies. For some time now, the Danish company has also been collaborating with technology companies Valo Health on an AI-supported "human-centric" platform for obesity, diabetes, and cardiovascular programs, as well as with Gensaic in the field of cardiometabolism. Novo Nordisk integrates AI into all phases of drug development – from data collection and target identification to design, patient selection, and regulatory documents.

The outlook for the shares of the two pharmaceutical giants has been improving recently. Bayer completed a lower technical reversal in the EUR 22.50 to EUR 24.50 zone and recently shot up to EUR 27.80. Analysts on the LSEG platform see 12-month price targets averaging EUR 28.30 – corresponding upgrades are likely to follow. The sell-off at Novo Nordisk also appears to be over. However, it will likely be years before the old highs of EUR 137 reappear. Both stocks are now highly interesting.

D-Wave – NVIDIA CEO fuels quantum computing

Quantum computing could prove to be the solution to complex computing problems in the coming years, as it is faster and uses significantly less energy. In this context, the stock market is celebrating new stocks on the price screen every day. The latest wave of buying was once again triggered by comments from NVIDIA co-founder and CEO Jensen Huang. In the CEO's view, quantum computer technology has reached a decisive turning point. He believes that the problem-solving capabilities of these systems will increase dramatically. Even NVIDIA's most advanced AI systems would need years of computing time to achieve this. The chip manufacturer is focusing on developing the necessary infrastructure and powerful software that will make quantum computers truly usable. A typical representative and currently highly hyped quantum stock is D-Wave. The expert in architectures and data processing services only generated revenue of USD 8.8 million in 2024, but as of yesterday, it had already surpassed the USD 5 billion mark. The Company recently reported that USD 95.8 million was raised overnight through the exercise of warrants. This means it now has sufficient funding to complete its major plans to distribute its new products. Analysts on the LSEG platform estimate revenue of around USD 25 million for the current year. Anyone who still thinks D-Wave's valuation is too low should jump on board!

Artificial intelligence has long since conquered all areas of the economy. In the pharmaceutical sector, Bayer and Novo Nordisk are already quite advanced in their use of new AI technologies. NetraMark is making a name for itself with a highly innovative approach, and its shares are also very attractively valued, given the wealth of expertise and patents it possesses. Investors should stay on the ball and make selective purchases.